



Review

Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles

Christian Wischke¹, Steven P. Schwendeman*

Department of Pharmaceutical Sciences, University of Michigan, 428 Church Street, Ann Arbor, MI 48109-1065, USA

ARTICLE INFO

Article history:

Received 17 March 2008

Received in revised form 29 April 2008

Accepted 29 April 2008

Available online 7 May 2008

Keywords:

PLGA

Biopharmaceutical classification system

Microencapsulation

Controlled release

Microparticle

Hydrophobic drug

ABSTRACT

Injectable biodegradable and biocompatible copolymers of lactic and glycolic acid (PLGA) are an important advanced delivery system for week-to-month controlled release of hydrophobic drugs (e.g., from biopharmaceutical classification system class IV), which often display poor oral bioavailability. The basic principles and considerations to develop such microparticle formulations is reviewed here based on a comprehensive study of papers and patents from the beginnings of hydrophobic drug encapsulation in polylactic acid and PLGA up through the very recent literature. Challenges with the diversity of drug properties, microencapsulation methods, and organic solvents are evaluated in light of the precedence of commercialized formulations and with a focus on decreasing the time to lab-scale encapsulation of water-insoluble drug candidates in the early stage of drug development. The influence of key formulation variables on final microparticle characteristics, and how best to avoid undesired microparticle properties, is analyzed mechanistically. Finally, concepts are developed to manage the common issues of maintaining sink conditions for in vitro drug release assays of hydrophobic compounds. Overall, against the backdrop of an increasing number of new, poorly orally available drug entities entering development, microparticle delivery systems may be a viable strategy to rescue an otherwise undeliverable substance.

© 2008 Elsevier B.V. All rights reserved.

Contents

1. Introduction	299
2. Drug properties relevant for microencapsulation and release	300
2.1. Recent trends in drug discovery and their implications on microencapsulation candidates	300
2.2. Drug solubility in aqueous and organic media	300
2.3. Drug stability	301
2.4. Drug-polymer interactions	301
2.5. Drug solid-state properties	301
3. Microencapsulation techniques for hydrophobic drugs	302
3.1. o/w emulsion technique	302
3.2. s/o/w technique	302
3.3. o/o method	303
3.4. w/o/w method	303
3.5. In situ forming microparticles	303
3.6. Salting out/phase separation	304
3.7. Melting techniques	304
3.8. Methods using supercritical fluids (SCF)	304
3.9. Spraying techniques	305
3.10. Ammonolysis	305
3.11. Rationale to select an encapsulation technique	305

* Corresponding author. Tel.: +1 734 615 6574; fax: +1 734 615 6162.

E-mail address: schwende@umich.edu (S.P. Schwendeman).¹ Present address: Center for Biomaterial Development and Berlin-Brandenburg Center for Regenerative Therapies, Institute of Polymer Research, GKSS Research Center Geesthacht GmbH, Kantstr. 55, 14513 Teltow, Germany.

4.	Solvents/cosolvents	305
4.1.	Dispersed phase solvents	305
4.1.1.	Solubility of polymer solvent in continuous phase	305
4.1.2.	Solubility of water in the polymer phase	307
4.1.3.	Solvent removal rate	307
4.1.4.	Solvent toxicity and regulatory considerations	308
4.2.	Cosolvents	309
5.	Polymer types	311
5.1.	Criteria for polymer selection	311
5.2.	Polymer degradation behavior	311
5.3.	Polymer mixtures and alternative PLGA copolymers	312
5.4.	Impact of drug properties and preparation procedure on polymer characteristics	312
6.	Controlling the polymer microparticle size	312
6.1.	Emulsification procedure	312
6.2.	Formulation parameters	313
6.3.	Particle size analysis	313
7.	Encapsulation efficiency	314
7.1.	Methods to determine the encapsulation efficiency	314
7.2.	Increasing the encapsulation efficiency	314
7.2.1.	Drug particle size	314
7.2.2.	Emulsifiers and drug solubility in the continuous phase	314
7.2.3.	Mass transfer of o-phase solvents and microparticle hardening	315
8.	Drug release from the microparticles	315
8.1.	In vitro assays—rationale for using sink conditions	315
8.2.	In vitro assays—media to maintain sink conditions	315
8.3.	In vitro assays—experimental set-up	316
8.4.	Controlling drug release	317
8.4.1.	Typical release pattern from PLGA microparticles	317
8.4.2.	Burst release	317
8.4.3.	Effect of particle size and porosity on the release rate	318
8.4.4.	Drug diffusion through the particle polymer matrix and effect of drug loading on release	318
8.4.5.	Onset of erosion-controlled release and attempts to obtain zero-order profiles	320
9.	Conclusions and future outlook	320
	Acknowledgments	320
	References	320

1. Introduction

The modern microencapsulation of bioactive substances continues to be an important formulation strategy since its inception about 70 years ago. Starting first with the aim to protect vitamins from oxidation (Taylor, 1938) it took some decades until polylactic acid (PLA) and later its copolymers, e.g., poly(lactic-co-glycolic acid) (PLGA), were evaluated as biodegradable and biocompatible polymers for drug delivery (Kulkarni et al., 1971; Cutright et al., 1971; Brady et al., 1973; Yolles and Sartori, 1980; Laurencin and Elgendy, 1994; Ignatius and Cleas, 1996; Anderson and Shive, 1997). Although already patented (Boswell and Scribner, 1973) and initially described by others (Nuwayser et al., 1977; Gardner et al., 1977), Beck, Tice, and coworkers were among the first to intensively study the encapsulation of hydrophobic drugs, i.e., steroids, and focus on their efficiency in vivo (Beck et al., 1979, 1980, 1981, 1983a,b; Tice and Lewis, 1983; Hahn et al., 1983; Cowsar et al., 1985). Despite the clear significance of these findings, these very early papers commonly did not focus in detail on both the experimental methods and the underlying concepts and principles of drug encapsulation. At the same time, the initial patents and reports on the delivery of peptide therapeutics, mostly for luteinizing hormone-releasing hormone analogs, were also becoming available (Chang, 1976; Sanders et al., 1984; Redding et al., 1984; Kent et al., 1986; Okada et al., 1987; Shimamoto, 1987; Ogawa et al., 1988a).

In the present literature of polymeric drug delivery devices, most publications focus on the encapsulation of larger molecules, e.g., peptides, proteins, and DNA/RNA for potential use as vaccines or as long-acting release (LAR[®]) drug formulations. Importantly, some

of these initiatives led to important pharmaceutical products and most of them are still on the market (e.g., Lupron Depot[®], Zoladex[®], Decapeptyl[®], Eligard[®], Enantone[®], Trenantone[®], Nutropin Depot[®], and Profact[®]). However, the vast majority of new chemical entities are neither peptides nor proteins, but molecules with a low molecular weight. Although no precise data are available, it has been estimated that up to 40% of all new chemical entities show poor solubility (Straub et al., 2005). Particularly with the development of BCS class IV drugs with a low solubility and a low permeability, which exhibit low oral bioavailability, companies are frequently faced with the choice to either develop or discard the early stage compound. In order to expedite this decision, the question of alternative delivery technologies needs to be discussed in the early stages of drug development. For certain drugs that (i) have a broad therapeutic window, (ii) require a low daily dose, and (iii) are going to be used for the long-term treatment of disease, injectable controlled release depots such as drug-loaded biodegradable polymer microparticles, may provide such an alternative delivery strategy, potentially rescuing an otherwise undeliverable drug.

Despite the literature focussing on the considerable challenges with injectable depots for biomacromolecules (e.g., peptide/protein stability, high encapsulation efficiency, and undesired initial burst release; Schwendeman et al., 1996; Sinha and Trehan, 2003; Jiang et al., 2005; Tamber et al., 2005), hydrophobic small molecules are an extremely significant class of drug substances and pose unique challenges in their own right. Therefore, this review focuses on hydrophobic drugs and seeks to develop some guiding principles to examine and solve key issues of their encapsulation in, and release from, injectable PLA and PLGA microparticles.

Download English Version:

<https://daneshyari.com/en/article/2505278>

Download Persian Version:

<https://daneshyari.com/article/2505278>

[Daneshyari.com](https://daneshyari.com)